Leerink Partners analyst Andrew Berens reiterated a Buy rating on Cullinan Management (CGEM – Research Report) yesterday and set a price target ...

New in vitro preclinical data show CLN-978 induced similar T cell activation, target B cell depletion, and cytokine production in human peripheral blood mononuclear cells (PBMC) derived from ...

Cullinan Therapeutics (CGEM) will present new preclinical data for CLN-978, its novel CD19xCD3 T cell engager. These data and the study schema for a planned Phase 1b study in patients with ...

Cullinan will present new in vitro preclinical data that provide further strong rationale for broad clinical development of CLN-978 in autoimmune ...

Cullinan will present new in vitro preclinical data that provide further strong rationale for broad clinical development of CLN-978 in autoimmune diseases Cullinan will share details of global ...

Cullinan will also have a Booth (#2304) in the Exhibit Hall. New in vitro preclinical data show CLN-978 induced similar T cell activation, target B cell depletion, and cytokine production in human ...

“These preclinical data show that CLN-978 is a highly potent T cell engager that leads to deep B cell depletion, supporting the broad development of CLN-978 as a potential new therapeutic option ...

Nov. 14, 2024 (GLOBE NEWSWIRE) -- Cullinan Therapeutics, Inc. (Nasdaq: CGEM), a biopharmaceutical company focused on developing modality-agnostic targeted therapies, will present new preclinical data ...

Nov. 04, 2024 (GLOBE NEWSWIRE) -- Cullinan Therapeutics, Inc. (Nasdaq: CGEM), a biopharmaceutical company focused on developing modality-agnostic targeted therapies, today announced the upcoming ...

New in vitro preclinical data show CLN-978 induced similar T cell activation, target B cell depletion, and cytokine production in human peripheral blood mononuclear cells (PBMC) derived from patients ...